Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
RegulatoryapprovedEnhertuPertuzumabPositive
AI Analysis
Summary
The European Medicines Agency's CHMP committee recommended approval of Enhertu in combination with Pertuzumab for first-line treatment of HER2 positive metastatic breast cancer, a significant regulatory milestone for Daiichi Sankyo's cancer therapy portfolio.
Outcome Details
CHMP recommended Enhertu plus Pertuzumab for approval as first-line treatment for HER2 positive metastatic breast cancer
Importance:8/10
Sentiment:
0.85
oncologybreast cancerHER2 positivecombination therapyEU approvalCHMP recommendationfirst-line treatment
Related Companies
Read the original article
Published by yahoo_finance on July 24, 2026 11:00 AM